MOTIV BTK Randomized Controlled Trial
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 292 participants.
Also called NCT05406622
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 292 participants
- Sponsor
- Registry
-
NCT05406622
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States, Germany
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05406622. Randomized; single masking; primary purpose treatment. Start 2022-06-10 (actual); primary completion 2026-04-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- MOTIV BTK Randomized Controlled Trial
- Condition
- Critical Limb Ischemia
- Intervention (Device)
- MOTIV Sirolimus-Eluting Bioresorbable Scaffold
- Intervention (Device)
- Percutaneous Transluminal Angioplasty (PTA) Device
- Lead sponsor
- REVA Medical, Inc.
Record details
- Record id
cardio:ct-nct05406622- Content hash
b5aa06436d2177e00a99cb3ade3de2dc7b72cf838984d81b86ac6d4fcdfbaad8